ReviewThe Journal of clinical investigation2014
Mechanisms of vancomycin resistance in Staphylococcus aureus.
Review in The Journal of clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
238 citing papers in PubMed, 3 syntheses or guidelines pooled it, 556 citations in OpenAlex.
- The prevalence of vancomycin-resistant Staphylococcus aureus in Ethiopia: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2023Pooled it
- Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Prevalence of methicillin-resistant Staphylococcus aureus in healthy Chinese population: A system review and meta-analysis.PloS one · 2019Pooled it
- A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Antimicrobial agents and chemotherapy · 2019Trial
- Genomic characterisation of vancomycin-resistant Enterococcus faecium with Tn1546-plasmid rep17 in obstetrics and gynaecology settings in Algeria.Molecular genetics and genomics : MGG · 2026Article
- Article
- Review
- Assessing Vancomycin-Formyl Peptide Conjugate Binding to the Surface of Resistant Staphylococcus aureus via Flow Cytometry.Chembiochem : a European journal of chemical biology · 2026Article
- Antimicrobial Resistance in Major Gram-Positive Pathogens: Beyond the Vancomycin Border.Antibiotics (Basel, Switzerland) · 2026Review
- Saturated fatty acids enhance daptomycin activity in a Fak-dependent manner in enterococci.Microbiology (Reading, England) · 2026Article
- Honey-biosynthesized silver nanoparticles against vancomycin-resistant enterococci: integrated antibacterial, antibiofilm, mechanistic and preliminary safety evaluation.Scientific reports · 2026Article
- Pathogen-Centric Activation of an Azoreductase-Responsive Antibody-Antibiotic Conjugate for the Targeted Eradication of MRSA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Characterization and antibacterial efficacy of the broad-host-range phage P108 against biofilm-forming and methicillin-resistant Staphylococcus aureus.Virus research · 2026Article
- A Single Point Mutation in GraS Drives Co-Evolution of Vancomycin Resistance and Virulence inMicroorganisms · 2026Article
- AMP-36 exhibits potent therapeutic efficacy against MRSA pneumonia through membrane-target mechanism.Scientific reports · 2026Article
- Vancomycin tolerance and dispersion of dual species biofilms ofbioRxiv : the preprint server for biology · 2026Article
- The toxic effects of α-hemolysin and β-hemolysin produced byFrontiers in immunology · 2026Review
- Vancomycin population pharmacokinetics in patients with burns.Frontiers in medicine · 2026Article
- Exploring the Antimicrobial Potential of a Peptide Against Mixed Biofilm of Staphylococcus aureus and Candida albicans.Probiotics and antimicrobial proteins · 2026Article
- Article
178 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Vancomycin is a glycopeptide antibiotic used for the treatment of Gram-positive bacterial infections. Traditionally, it has been used as a drug of last resort; however, clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) strains with decreased susceptibility to vancomycin (vancomycin intermediate-resistant S. aureus [VISA]) and more recently with high-level vancomycin resistance (vancomycin-resistant S. aureus [VRSA]) have been described in the clinical literature. The rare VRSA strains carry transposon Tn1546, acquired from vancomycin-resistant Enterococcus faecalis, which is known to alter cell wall structure and metabolism, but the resistance mechanisms in VISA isolates are less well defined. Herein, we review selected mechanistic aspects of resistance in VISA and summarize biochemical studies on cell wall synthesis in a VRSA strain. Finally, we recapitulate a model that integrates common mechanistic features of VRSA and VISA strains and is consistent with the mode of action of vancomycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.